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ALT

:   alanine aminotransferase

Bambi

:   bone morphogenetic protein and activin membrane--bound inhibitor

BW

:   body weight

CE

:   cholesterol ester

Col1a1

:   collagen 1a1

Col1a2

:   collagen 1a2

DAPI

:   4′,6‐diamidino‐2‐phenylindole

FC

:   free cholesterol

FFA

:   free fatty acid

GFAP

:   glial fibrillary acidic protein

GTT

:   glucose tolerance test

HDL

:   high‐density lipoprotein

H&E

:   hematoxylin and eosin

HFC

:   high fat/high cholesterol

HSC

:   hepatic stellate cell

IL

:   interleukin

ITT

:   insulin tolerance test

LDL

:   low‐density lipoprotein

LPL

:   lipoprotein lipase

LPS

:   lipopolysaccharide

mRNA

:   messenger RNA

MT

:   Masson trichrome

MβCD

:   methyl‐β‐cyclodextrin

NAFL

:   nonalcoholic fatty liver

NAFLD

:   nonalcoholic fatty liver disease

NASH

:   nonalcoholic steatohepatitis

PBS

:   phosphate‐buffered saline

pSTAT3

:   phosphorylated signal transducer and activator of transcription 3

PTT

:   pyruvate tolerance test

SMA

:   smooth muscle actin

STAT3

:   signal transducer and activator of transcription 3

TC

:   total cholesterol

TG

:   triglyceride

TGF‐β

:   transforming growth factor‐β

TLR4

:   toll‐like receptor 4

VLDL

:   very low‐density lipoprotein

With the increase in the incidence of obesity, the number of patients with nonalcoholic fatty liver disease (NAFLD) has increased worldwide, reaching approximately 25% of adults in the United States.[1](#hep41383-bib-0001){ref-type="ref"} NAFLD is considered a hepatic manifestation of obesity and metabolic syndrome (including dyslipidemia, hypertension, and impaired glucose tolerance), because many patients with NAFLD manifest these conditions as background factors. Nonalcoholic steatohepatitis (NASH), which accounts for 20% to 30% of NAFLD, is a progressive liver disease that results in liver cirrhosis and liver cancer. In the United States, approximately 6% of adults are diagnosed with NASH, and approximately 2% progress to cirrhosis due to NASH; therefore, NASH is expected to become the leading cause of liver transplantation in the United States by 2020.[1](#hep41383-bib-0001){ref-type="ref"}, [2](#hep41383-bib-0002){ref-type="ref"}

Because the number of patients with NASH is rapidly increasing worldwide, establishing treatment methods and evaluating its pathophysiological mechanisms represent urgent issues. Although the two‐hit theory[3](#hep41383-bib-0003){ref-type="ref"} and multiple parallel--hit hypothesis[4](#hep41383-bib-0004){ref-type="ref"} have been proposed as the pathophysiological mechanisms of NASH, the details are not yet clear. The extent of hepatic fibrosis has been recently considered the most important liver tissue finding for evaluating the prognosis of patients with NASH.[1](#hep41383-bib-0001){ref-type="ref"}, [5](#hep41383-bib-0005){ref-type="ref"}, [6](#hep41383-bib-0006){ref-type="ref"} Furthermore, it is assumed that metabolic syndrome and obesity, as background factors, modify the pathophysiological mechanism of NASH.

Lipoprotein lipase (LPL) is widely known to play a central role in incorporating plasma lipids into tissues and regulating lipid metabolism and the energy balance in the human body.[7](#hep41383-bib-0007){ref-type="ref"} LPL is produced primarily by parenchymal cells in the adipose tissue, heart, and skeletal muscle. LPL hydrolyzes triglycerides (TGs) from serum lipoproteins and functions in incorporating free fatty acids (FFAs) produced as a result of hydrolysis in each tissue. In recent years, LPL has also been reported to promote the binding of lipoproteins to their receptors, and its involvement in diseases associated with atherosclerosis has been noted.[7](#hep41383-bib-0007){ref-type="ref"}, [8](#hep41383-bib-0008){ref-type="ref"} Furthermore, its role in many aspects of obesity, such as insulin resistance and dyslipidemia, has also been reported.[9](#hep41383-bib-0009){ref-type="ref"} In contrast, LPL expression in the liver is relatively high at birth but gradually decreases; in adults, almost no expression is observed.[10](#hep41383-bib-0010){ref-type="ref"} Therefore, the role of hepatic LPL in human pathology has not yet been clarified, although pathological changes following introduction of the *LPL* gene into the liver in a mouse model have been observed.[9](#hep41383-bib-0009){ref-type="ref"}, [11](#hep41383-bib-0011){ref-type="ref"}

In the present study, we demonstrate that LPL expression is elevated, specifically in hepatic stellate cells (HSCs), but not in liver parenchymal cells, as human NAFLD progresses. Furthermore, an HSC‐specific LPL‐deficient mouse strain was used to clarify the mechanistic details underlying the role of LPL in the development of NASH pathology.

Materials and Methods {#hep41383-sec-0002}
=====================

Animal Studies {#hep41383-sec-0003}
--------------

Eight‐week‐old male C57BL6/J mice and Wistar rats were purchased from CLEA Japan (Tokyo, Japan). B6.129S4‐Lpltm1Ijg/J mice (LPL‐floxed \[*Lpl^fl/fl^*\] mice) were purchased from the Jackson Laboratory (Bar Harbor, ME). HSC‐specific LPL‐deficient (*Lpl^HSC‐KO^*) mice were obtained by mating glial fibrillary acidic protein (*Gfap*)‐*Cre* transgenic (*Cre^Tg^*) mice[12](#hep41383-bib-0012){ref-type="ref"} with *Lpl^fl/fl^* mice. B6.129‐Tlr4tm1Aki/Obs (toll‐like receptor 4 \[*Tlr4*\]*^−/−^* mice) were purchased from Oriental BioService (Kyoto, Japan). *Tlr4^−/−^Lpl^fl/fl^* and *Tlr4^−/−^Lpl^HSC‐KO^* mice were obtained by mating *Lpl^HSC‐KO^* mice with *Tlr4^−/−^* mice. *Lpl^fl/fl^*, *Lpl^HSC‐KO^*, *Tlr4^−/−^Lpl^fl/fl^*, or *Tlr4^−/−^Lpl^HSC‐KO^* mice were fed a CE‐2 (CLEA Japan) or a high‐fat/high‐cholesterol (HFC) diet (CLEA Japan) for 4 or 24 weeks to induce the NAFLD model as described.[13](#hep41383-bib-0013){ref-type="ref"} The glucose tolerance test (GTT), insulin tolerance test (ITT), and pyruvate tolerance test (PTT) were performed using LabAssay Glucose (FUJIFILM Wako Pure Chemicals) as described.[12](#hep41383-bib-0012){ref-type="ref"} For GTT, at 21 weeks into the diet, the mice were given glucose (1.5 g/kg body weight \[BW\]) intraperitoneally after being fasted for 16 hours. For ITT, at 22 weeks into the diet, the mice were given insulin (0.5 U/kg BW) intraperitoneally after being fasted for 4 hours. For PTT, at 23 weeks into the diet, the mice were given pyruvate (2 g/kg BW) intraperitoneally after being fasted for 16 hours. For acute administration experiments, intralipid (20 mg/g BW), recombinant leptin (5 mg/g BW), or recombinant interleukin‐6 (IL‐6) (500 mg/g BW) was given to 8‐week‐old male C57BL6/J mice. Four hours after administration, mouse livers were extracted.

The mice were maintained under specific pathogen‐free conditions at the Center for Laboratory Animal Science, National Defense Medical College. All animals received humane care in compliance with the National Research Council criteria outlined in the *Guide for the Care and Use of Laboratory Animals* prepared by the U.S. National Academy of Sciences and published by the U.S. National Institutes of Health (Bethesda, MD). All experimental protocols were approved by the National Defense Medical College Animal Use and Care Committee, and all methods were carried out in accordance with relevant guidelines and regulations.

Statistical Analysis {#hep41383-sec-0004}
--------------------

All data are expressed as the means ± SEMs. Statistical analyses were undertaken using an unpaired two‐tailed Student *t* test or a one‐way analysis of variance using Tukey's *post hoc* test for multiple comparisons. Pearson's correlation was used to verify the relationship between the variables. A *P* value of less than 0.05 was considered to indicate statistically significant differences.

Results {#hep41383-sec-0005}
=======

Serum Obesity‐Related Factors Elevate LPL Expression, Specifically in HSCs, in Mice and Patients With NAFLD {#hep41383-sec-0006}
-----------------------------------------------------------------------------------------------------------

*LPL* messenger RNA (mRNA) expression was significantly higher in the liver of patients with NAFLD than in that of normal subjects (Fig. [1](#hep41383-fig-0001){ref-type="fig"}A). Furthermore, in liver samples derived from patients with NASH, the expression of *LPL* mRNA was significantly increased compared with that in the liver of patients with nonalcoholic fatty liver (NAFL). Immunofluorescence double staining of LPL and GFAP revealed that LPL is expressed specifically in HSCs and that, in the liver of patients with NAFLD, LPL expression is significantly enhanced, specifically in HSCs (Fig. [1](#hep41383-fig-0001){ref-type="fig"}A). In addition, with the progression of NAFLD, its expression significantly increased (Fig. [1](#hep41383-fig-0001){ref-type="fig"}A). A significant correlation was also observed between the levels of serum obesity‐related factors, such as FFAs, leptin, and IL‐6, and the number of LPL‐positive HSCs in patients with NAFLD (Fig. [1](#hep41383-fig-0001){ref-type="fig"}B). Similarly, a significant correlation was observed between the respective serum levels and hepatic *LPL* expression (Fig. [1](#hep41383-fig-0001){ref-type="fig"}C). Furthermore, the intravenous administration of intralipid, leptin, and IL‐6 significantly increased *Lpl* mRNA expression in both mouse livers and HSCs (Fig. [1](#hep41383-fig-0001){ref-type="fig"}D). Moreover, immunofluorescence double staining of GFAP and LPL revealed that LPL expression was elevated following the administration of these factors, specifically in HSCs (Fig. [1](#hep41383-fig-0001){ref-type="fig"}E). In mouse primary cultured HSCs, the administration of FFA, leptin, and IL‐6 additively increased *Lpl* mRNA expression (Fig. [1](#hep41383-fig-0001){ref-type="fig"}F).

![Serum obesity‐related factors elevate LPL expression, specifically in HSCs, in mice and patients with NAFLD. (A‐C) Human serum and liver tissue samples from controls (n = 14), patients with NAFL (n = 21), and patients with NASH (n = 54). (A) (Left panel) Hepatic *LPL* mRNA expression. (Middle panel) Representative immunofluorescence double‐staining images of GFAP (green) and LPL (red); co‐staining (yellow). Nuclei were stained with 4′,6‐diamidino‐2‐phenylindole (DAPI) (blue). Scale bars: 50 μM (upper) and 25 μM (lower). (Right panel) Quantification of GFAP/LPL double‐positive cells and LPL staining. \*\**P* \< 0.01 and \**P* \< 0.05 versus control (normal) liver samples. (B) Correlation between the number of hepatic LPL‐positive cells and FFA, leptin, or IL‐6 serum levels. (C) Correlation between hepatic *LPL* expression and serum FFA, leptin, or IL‐6 levels. (D) *Lpl* mRNA levels in the liver (left panel) and freshly isolated HSCs (right panel) in wild‐type mice after intravenous administration of phosphate‐buffered saline (PBS), intralipid, leptin, or IL‐6 (n = 5/group). \*\**P* \< 0.01 and \**P* \< 0.05 versus the PBS‐treated group. (E) (Upper panel) Representative immunofluorescence double‐staining images for GFAP (green) and LPL (red). (Lower panel) Quantification of GFAP/LPL double‐positive cells and LPL staining in liver tissue samples from 8‐week‐old male wild‐type C57BL6/J mice 4 hours after intravenous administration of PBS, intralipid, leptin, or IL‐6 (n = 5/group); co‐staining (yellow). Nuclei were stained with DAPI (blue). Scale bars: 50 μM (upper) and 25 μM (lower). \*\**P* \< 0.01 versus the PBS‐treated group. (F) *Lpl* mRNA levels in primary wild‐type C57BL6/J HSCs, freshly isolated, cultured overnight, and treated with various combinations of palmitate (200 μM), leptin (100 ng/mL), and IL‐6 (100 ng/mL) for 6 hours (n = 5/group). \*\**P* \< 0.01 versus PBS‐treated HSCs.](HEP4-3-1098-g001){#hep41383-fig-0001}

Serum Obesity‐Related Factors Elevate LPL Expression Through Signal Transducer and Activator of Transcription 3 Signaling in HSCs in Human and Murine NAFLD {#hep41383-sec-0007}
-----------------------------------------------------------------------------------------------------------------------------------------------------------

Immunofluorescence double staining of phosphorylated signal transducer and activator of transcription 3STAT3 (pSTAT3) and LPL in mouse liver tissues after the intravenous administration of obesity‐related factors revealed that LPL expression is elevated, specifically in pSTAT3‐positive cells (Supporting Fig. [S1](#hep41383-sup-0001){ref-type="supplementary-material"}). In addition, the elevation of *LPL* mRNA expression in human and mouse primary cultured HSCs following the addition of obesity‐related factors was abolished by the simultaneous administration of a STAT3 inhibitor (Supporting Fig. [S1](#hep41383-sup-0001){ref-type="supplementary-material"}). Immunofluorescence double staining of pSTAT3 and LPL in human NAFLD liver tissues showed that LPL‐positive and pSTAT3‐positive cells almost overlapped (Fig. [2](#hep41383-fig-0002){ref-type="fig"}A). The number of pSTAT3/LPL double‐positive cells increased significantly with the progression of NAFLD (Fig. [2](#hep41383-fig-0002){ref-type="fig"}A). The number of GFAP/pSTAT3 double‐positive cells was significantly correlated with the number of LPL‐positive cells (Fig. [2](#hep41383-fig-0002){ref-type="fig"}A).

![Serum obesity‐related factors elevate LPL expression through STAT3 signaling in HSCs from patients with NAFLD and in a mouse model of NAFLD. (A) Human liver tissue samples from controls (n = 14), patients with NAFL (n = 21), and patients with NASH (n = 54). (Left panel) Representative immunofluorescence double‐staining images of LPL (green) and pSTAT3 (red). Nuclei were stained with DAPI (blue). pSTAT3/nucleus co‐staining (purple). Scale bars: 50 μM (upper) and 25 μM (lower). (Middle panel) Quantification of pSTAT3/LPL double‐positive cells. (Right panel) Correlation between LPL‐positive and pSTAT3/GFAP double‐positive cells. \*\**P* \< 0.01 and \**P* \< 0.05 versus control (normal) liver samples. (B‐G) Eight‐week‐old male *Lpl^fl/fl^* and *Lpl^HSC‐KO^* mice were fed an HFC diet for 4 weeks (n = 6/group) or 24 weeks (n = 7/group) to induce the NAFLD mouse model or a control diet for 24 weeks (n = 6/group). (B) (Left panel) Hepatic *Lpl* mRNA expression. (Right panel) Hepatic LPL expression. \*\**P* \< 0.01 versus *Lpl^fl/fl^* mice fed a control diet. (C) Representative immunofluorescence double‐staining images for GFAP (green) and LPL (red) in liver tissue samples; co‐staining (yellow). Nuclei were stained with DAPI (blue). Scale bars: 50 μM (upper) and 25 μM (lower). (D) LPL expression in freshly isolated HSCs. (E) (Left panels) Correlation between the number of hepatic LPL‐positive cells and FFA, leptin, or IL‐6 serum levels in *Lpl^fl/fl^* mice. (Right panels) Correlation between the hepatic *Lpl* mRNA expression and FFA, leptin, or IL‐6 serum levels in *Lpl^fl/fl^* mice. (F) (Left panel) Representative immunofluorescence double‐staining images for LPL (green) and pSTAT3 (red) in liver tissue samples from *Lpl^fl/fl^* mice. Nuclei were stained with DAPI (blue). pSTAT3/nucleus co‐staining (purple). Scale bars: 50 μM (upper) and 25 μM (lower). (Middle panel) Quantification of hepatic pSTAT3/LPL double‐positive cells in *Lpl^fl/fl^* mice. (Right panel) Correlation between the number of hepatic LPL‐positive and hepatic pSTAT3/GFAP double‐positive cells in *Lpl^fl/fl^* mice. \*\**P* \< 0.01 versus *Lpl^fl/fl^* mice fed a control diet.](HEP4-3-1098-g002){#hep41383-fig-0002}

Next, to elucidate the role of LPL in HSCs on NAFLD pathology, *Lpl^HSC‐KO^* mice were generated. *Lpl^HSC‐KO^* mice were obtained by crossing *Lpl^fl/fl^* mice with *Gfap‐Cre^Tg^* mice. CRE expression was specifically localized in the GFAP‐positive HSCs in the livers of *Lpl^HSC‐KO^* mice as described[12](#hep41383-bib-0012){ref-type="ref"} (Supporting Fig. [S2](#hep41383-sup-0002){ref-type="supplementary-material"}). *Lpl^fl/fl^* and *Lpl^HSC‐KO^* mice were fed an HFC diet for 4 weeks to induce the NAFL model and an HFC diet for 24 weeks to induce the NASH model. Similar to that in human NAFLD, the hepatic *Lpl* mRNA levels increased significantly with NAFLD progression in our mouse model (Fig. [2](#hep41383-fig-0002){ref-type="fig"}B). In *Lpl^HSC‐KO^* mouse livers, the expression of LPL mRNA and protein was scarcely observed (Fig. [2](#hep41383-fig-0002){ref-type="fig"}B). Moreover, immunofluorescence double staining of GFAP and LPL showed that LPL is localized to HSCs, and its expression increased with NAFLD progression (Fig. [2](#hep41383-fig-0002){ref-type="fig"}C). Using HSCs isolated from the livers of NAFLD mice, we also observed that LPL expression in HSCs significantly increased with the progression of NAFLD (Fig. [2](#hep41383-fig-0002){ref-type="fig"}D). Furthermore, the serum levels of obesity‐related factors, such as FFA, leptin and IL‐6, were significantly correlated with the number of LPL‐positive HSCs in the mouse NAFLD model (Fig. [2](#hep41383-fig-0002){ref-type="fig"}E). The levels of serum FFA, leptin, and IL‐6 were also significantly correlated with hepatic *Lpl* mRNA expression (Fig. [2](#hep41383-fig-0002){ref-type="fig"}E). Furthermore, immunofluorescence double staining of pSTAT3 and LPL in liver tissues revealed that LPL‐positive and pSTAT3‐positive cells overlap in mouse NAFLD liver similar to the pattern observed in human NAFLD (Fig. [2](#hep41383-fig-0002){ref-type="fig"}F). As NAFLD progressed, the number of pSTAT3/LPL double‐positive cells increased significantly (Fig. [2](#hep41383-fig-0002){ref-type="fig"}F). Moreover, a significant correlation was observed between the numbers of GFAP/pSTAT3 double‐positive and LPL‐positive cells (Fig. [2](#hep41383-fig-0002){ref-type="fig"}F).

LPL Deficiency in HSCs Reduces the Progression of Liver Fibrosis in Murine NAFLD {#hep41383-sec-0008}
--------------------------------------------------------------------------------

*Lpl^fl/fl^* and *Lpl^HSC‐KO^* mice were fed either a control or an HFC diet for 24 weeks to induce NASH. In the NASH mouse model, hepatic fibrosis was significantly enhanced compared with that in control mice; liver fibrosis was significantly reduced in *Lpl^HSC‐KO^* mice compared with that in *Lpl^fl/fl^* mice, as shown by Masson trichrome (MT) and α‐smooth muscle actin (SMA) staining in the liver (Fig. [3](#hep41383-fig-0003){ref-type="fig"}A). The hepatic expression of collagen 1a1 (*Col1a1*), *Col1a2*, αSMA (*Acta2*), and transforming growth factor‐β (*Tgfb*) mRNA was significantly increased in the NASH model; the hepatic expression of *Col1a1*, *Col1a2*, and *Acta2* mRNA was significantly reduced in *Lpl^HSC‐KO^* mice compared with that in *Lpl^fl/fl^* mice (Fig. [3](#hep41383-fig-0003){ref-type="fig"}B). In the NASH model, serum alanine aminotransferase (ALT) and liver TG levels were significantly elevated compared with those in control mice. In contrast, no significant differences were observed between *Lpl^fl/fl^* and *Lpl^HSC‐KO^* mice regarding these levels (Fig. [3](#hep41383-fig-0003){ref-type="fig"}C,D). BW, serum TG level, total cholesterol (TC) level, and glucose tolerance were also not significantly different between *Lpl^fl/fl^* and *Lpl^HSC‐KO^* mice (Supporting Fig. [S3](#hep41383-sup-0003){ref-type="supplementary-material"}). GTT, ITT, and PTT results were not significantly different between *Lpl^fl/fl^* and *Lpl^HSC‐KO^* mice at each time point (0, 30, 60, and 120 minutes; Supporting Fig. [S3](#hep41383-sup-0003){ref-type="supplementary-material"}). In addition, the hepatic expression of *Tnf*, *Adgre1* and *Cd68,* markers of Kupffer cell activation and accumulation in the liver, significantly increased in the liver in the NASH model when compared with that in control mice, whereas no significant differences were observed between *Lpl^fl/fl^* and *Lpl^HSC‐KO^* mice (Fig. [3](#hep41383-fig-0003){ref-type="fig"}E). In addition, we did not detect any significant differences in macrophage recruitment to the liver between *Lpl^fl/fl^* and *Lpl^HSC‐KO^* mice (Supporting Fig. [S4](#hep41383-sup-0004){ref-type="supplementary-material"}).

![LPL deficiency in HSCs reduces the progression of liver fibrosis in murine NAFLD. Eight‐week‐old male *Lpl^fl/fl^* and *Lpl^HSC‐KO^* mice were fed an HFC diet for 4 weeks (n = 6/group) or 24 weeks (n = 7/group) to induce an NAFLD mouse model or were fed a control diet for 24 weeks (n = 6/group). (A) (Left panel) Representative hematoxylin and eosin (H&E)--stained, MT‐stained, and αSMA‐immunostained liver sections. Scale bars: 200 μM (H&E‐stained and MT‐stained sections) and 100 μM (αSMA‐immunostained sections). (Right panel) Quantification of MT staining and αSMA staining in liver sections. (B) Hepatic levels of *Col1a1*, *Col1a2*, *Acta2*, and *Tgfb* mRNA. (C) Serum ALT levels. (D) Hepatic TG levels. (E) Hepatic levels of *Tnf*, *Adgre1*, and *Cd68* mRNA. \*\**P* \< 0.01 versus *Lpl^fl/fl^* mice fed a control diet.](HEP4-3-1098-g003){#hep41383-fig-0003}

In Murine NASH, LPL Deficiency in HSCs Reduces the Activation of HSCs in a TLR4‐Dependent Manner, Leading to Alleviation of Liver Fibrosis {#hep41383-sec-0009}
------------------------------------------------------------------------------------------------------------------------------------------

The *Col1a1*, *Col1a2*, and *Acta2* mRNA expression in HSCs in the NASH mouse model increased significantly compared with that in HSCs from control mice; this increase in expression was significantly reduced in *Lpl^HSC‐KO^* HSCs compared with that in *Lpl^fl/fl^* HSCs (Fig. [4](#hep41383-fig-0004){ref-type="fig"}A). In *Lpl^fl/fl^* HSCs, the mRNA levels of bone morphogenetic protein and activin membrane--bound inhibitor (Bambi), a pseudoreceptor of TGF‐β, were significantly lower in the NASH mouse model than in control mice; in addition, they were significantly higher in *Lpl^HSC‐KO^* HSCs than in *Lpl^fl/fl^* HSCs (Fig. [4](#hep41383-fig-0004){ref-type="fig"}A). In *Lpl^fl/fl^* HSCs, TLR4 protein levels significantly increased in NASH mice when compared with those in control mice; this increase was significantly suppressed in *Lpl^HSC‐KO^* HSCs compared with that in *Lpl^fl/fl^* HSCs (Fig. [4](#hep41383-fig-0004){ref-type="fig"}B). However, we also observed no significant differences in *Tlr4* mRNA levels in HSCs among these groups (Fig. [4](#hep41383-fig-0004){ref-type="fig"}B).

![LPL deficiency in HSCs reduces the activation of HSCs in a TLR4‐dependent manner in murine NASH. (A,B) Eight‐week‐old male *Lpl^fl/f^* ^l^ and *Lpl^HSC‐KO^* mice were fed a control diet (n = 6/group) or an HFC diet (n = 7/group) for 24 weeks. (A) Quantification of *Col1a1*, *Col1a2*, *Acta2*, and *Bambi* mRNA in HSCs freshly isolated from mice. (B) (Left panel) Western blot analysis and quantification of TLR4 protein levels in freshly isolated HSCs. (Right panel) Quantification of *Tlr4* mRNA in freshly isolated HSCs. \*\**P* \< 0.01 versus HSCs from *Lpl^fl/fl^* mice fed a control diet. (C‐E) Eight‐week‐old male *Tlr4^−/−^Lpl^fl/fl^* and *Tlr4^−/−^Lpl^HSC‐KO^* mice were fed a control diet or an HFC diet for 24 weeks (n = 5/group). (C) (Left panel) Representative H&E‐stained, MT‐stained, and αSMA‐immunostained liver sections. Scale bars: 200 μM (H&E‐stained and MT‐stained sections) and 100 μM (αSMA‐immunostained sections). (Right panel) Quantification of MT staining and αSMA staining in liver sections. (D) Hepatic levels of *Col1a1*, *Col1a2*, and *Acta2* mRNA. (E) Quantification of *Bambi* mRNA in freshly isolated HSCs. \*\**P* \< 0.01 and \**P* \< 0.05 versus *Tlr4^−/−^Lpl^fl/fl^* mice fed a control diet.](HEP4-3-1098-g004){#hep41383-fig-0004}

Therefore, we generated double‐mutant *Tlr4^−/−^Lpl^fl/fl^* and *Tlr4^−/−^Lpl^HSC‐KO^* mice, to clarify whether LPL expression in HSCs exacerbates liver fibrosis in NASH through TLR4 signaling. The double‐mutant mice were fed an HFC diet for 24 weeks to induce NASH; we could not observe any significant differences in liver fibrosis and HSC activation between *Tlr4^−/−^Lpl^fl/fl^* and *Tlr4^−/−^Lpl^HSC‐KO^* mice, as shown by MT and αSMA staining (Fig. [4](#hep41383-fig-0004){ref-type="fig"}C). Moreover, no significant differences in the hepatic mRNA expression of *Col1a1*, *Col1a2*, and *Acta2* or in *Bambi* mRNA levels in HSCs were observed between these mouse strains (Fig. [4](#hep41383-fig-0004){ref-type="fig"}D,E). These results and the results in Fig. [3](#hep41383-fig-0003){ref-type="fig"} revealed that LPL deficiency in HSCs reduces the progression of liver fibrosis in murine NAFLD in a TLR4‐dependent manner. Furthermore, no significant differences in serum ALT levels or the hepatic mRNA levels of *Tnf*, *Adgre1*, and *Cd68* were observed between *Tlr4^−/−^Lpl^fl/fl^* and *Tlr4^−/−^Lpl^HSC‐KO^* mice (Supporting Fig. [S5](#hep41383-sup-0005){ref-type="supplementary-material"}).

Nonenzymatic Effect of LPL Plays a Key Role in Cholesterol Uptake in HSCs in Murine NASH {#hep41383-sec-0010}
----------------------------------------------------------------------------------------

*Lpl^fl/fl^* and *Lpl^HSC‐KO^* mice were fed either a control or an HFC diet for 24 weeks to induce NASH. The accumulation of TC and free cholesterol (FC) in HSCs significantly increased in NASH mice when compared with that in control mice; the increase was significantly reduced in HSCs derived from *Lpl^HSC‐KO^* mice compared with that in HSCs from *Lpl^fl/fl^* mice (Fig. [5](#hep41383-fig-0005){ref-type="fig"}A). No significant differences in TC and FC accumulation were observed between the livers of *Lpl^HSC‐KO^* and *Lpl^fl/fl^* mice (Fig. [5](#hep41383-fig-0005){ref-type="fig"}B). Next, to investigate the role of LPL in cholesterol uptake in HSCs, we examined cholesterol uptake into HSCs when intravenously administering ^14^C‐labeled lipoproteins to NASH or control mice. The ^14^C‐labeled chylomicron uptake into HSCs in *Lpl^fl/fl^* mice was significantly elevated in the NASH mouse model compared with that in control mice; this increase was significantly suppressed in *Lpl^HSC‐KO^* mice compared with that in *Lpl^fl/fl^* mice (Fig. [5](#hep41383-fig-0005){ref-type="fig"}C). Furthermore, the uptake was not affected by the pre‐administration of an LPL enzyme inhibitor, orlistat, into the mice (Fig. [5](#hep41383-fig-0005){ref-type="fig"}C). Similarly, the ^14^C‐labeled very low‐density lipoprotein (VLDL) or low‐density lipoprotein (LDL) uptake into HSCs in *Lpl^fl/fl^* mice was significantly elevated in the NASH mouse model compared with that in control mice; this increase was significantly suppressed in *Lpl^HSC‐KO^* mice compared with that in *Lpl^fl/fl^* mice (Fig. [5](#hep41383-fig-0005){ref-type="fig"}D,E). Uptake levels were not affected by the pre‐administration of orlistat into the mice (Fig. [5](#hep41383-fig-0005){ref-type="fig"}D,E). Orlistat inhibits the enzyme activity of LPL, but it does not inhibit the nonenzymatic function of LPL, which means that nonenzymatic effect of LPL plays a key role in cholesterol uptake in HSCs in murine NASH. In contrast, the uptake of ^14^C‐labeled high‐density lipoprotein (HDL) into HSCs did not lead to any significant differences among the treated groups and was not affected by the pre‐administration of orlistat into the mice (Fig. [5](#hep41383-fig-0005){ref-type="fig"}F). Furthermore, the total liver uptake of each of the ^14^C‐labeled chylomicrons, VLDL, LDL and HDL, did not show any significant differences among the treated groups (Fig. [5](#hep41383-fig-0005){ref-type="fig"}C‐F).

![Nonenzymatic effect of LPL plays an important role in cholesterol uptake in HSCs in murine NASH. (A,B) Eight‐week‐old male *Lpl^fl/f^* ^l^ and *Lpl^HSC‐KO^* mice were fed a control diet (n = 6/group) or an HFC diet (n = 7/group) for 24 weeks. (A) Quantification of the TC, FC, and cholesterol ester (CE) content in HSCs freshly isolated from mice. (B) Hepatic levels of TC, FC, and CE. \**P* \< 0.05 versus *Lpl^fl/fl^* mice fed a control diet. (C‐F) Livers of *Lpl^fl/f^* ^l^ or *Lpl^HSC‐KO^* mice, which had been fed a control diet or an HFC diet for 24 weeks and then given the LPL enzyme inhibitor orlistat or vehicle, were perfused with ^14^C‐labeled lipoproteins (n = 5/group). (C) Quantification of ^14^C‐labeled chylomicrons in livers and freshly isolated HSCs. (D) Quantification of ^14^C‐labeled VLDL in livers and freshly isolated HSCs. (E) Quantification of ^14^C‐labeled LDL in livers and freshly isolated HSCs. (F) Quantification of ^14^C‐labeled HDL in livers and freshly isolated HSCs. \*\**P* \< 0.01 versus *Lpl^fl/fl^* mice fed a control diet and administered vehicle.](HEP4-3-1098-g005){#hep41383-fig-0005}

Nonenzymatic Cholesterol Uptake Into HSCs Through LPL Promotes TGF‐β‐Induced HSC Activation {#hep41383-sec-0011}
-------------------------------------------------------------------------------------------

The effect of cholesterol uptake by LPL on HSC activation was examined using primary cultured *Lpl^fl/fl^* and *Lpl^HSC‐KO^* HSCs. The administration of chylomicrons or LDL significantly increased the amount of TC and FC in *Lpl^fl/fl^* HSCs, whereas LPL deficiency significantly suppressed this increase (Fig. [6](#hep41383-fig-0006){ref-type="fig"}A). Cholesterol uptake was not affected by the simultaneous administration of orlistat (Fig. [6](#hep41383-fig-0006){ref-type="fig"}A). Furthermore, the simultaneous administration of methyl‐β‐cyclodextrin (MβCD), a membrane‐impermeable cholesterol‐binding agent that depletes cholesterol,[14](#hep41383-bib-0014){ref-type="ref"}, [15](#hep41383-bib-0015){ref-type="ref"} depleted FC in HSCs (Fig. [6](#hep41383-fig-0006){ref-type="fig"}A).

![Nonenzymatic cholesterol uptake into HSCs by LPL promotes the TGF‐β‐induced HSC activation. (A,B) Primary *Lpl^fl/f^* ^l^ or *Lpl^HSC‐KO^* HSCs were freshly isolated, cultured overnight, and treated with PBS, chylomicrons (200 μg/mL), or LDL (200 μg/mL) for 6 hours after the addition of PBS, MβCD (4 mM), or orlistat (75 μM) (n = 5/group). (A) Quantification of TC, FC, and CE levels in HSCs. (B) TLR4 protein levels in HSCs. \*\**P* \< 0.01 versus control *Lpl^fl/fl^* HSCs treated with PBS. (C,D) Primary *Lpl^fl/f^* ^l^ or *Lpl^HSC‐KO^* HSCs were freshly isolated, cultured overnight, and treated with PBS, chylomicrons (200 μg/mL), or LDL (200 μg/mL) for 6 hours after the addition of PBS, MβCD (4 mM), or orlistat (75 μM). The HSCs were further treated with LPS (100 ng/mL) for 6 hours and then stimulated with TGF‐β (1 ng/mL) for 6 hours (n = 5/group). (C) Quantification of *Bambi* mRNA in HSCs. (D) Quantification of *Col1a1*, *Col1a2*, and *Acta2* mRNA in HSCs. \*\**P* \< 0.01 versus control *Lpl^fl/fl^* HSCs treated with PBS.](HEP4-3-1098-g006){#hep41383-fig-0006}

Next, we evaluated the TLR4 protein levels in HSCs. The TLR4 protein expression was consistent with the intracellular FC level in HSCs; TLR4 levels significantly increased following the administration of chylomicrons or LDL in *Lpl^fl/fl^* HSCs, whereas this increase was significantly suppressed in *Lpl^HSC‐KO^* HSCs compared with that in *Lpl^fl/fl^* HSCs (Fig. [6](#hep41383-fig-0006){ref-type="fig"}B). The concurrent administration of MβCD dramatically decreased TLR4 protein levels in HSCs, whereas the levels were not affected by the simultaneous administration of orlistat (Fig. [6](#hep41383-fig-0006){ref-type="fig"}B). Accumulation of FC in HSCs increases TLR4 protein levels through the suppression of the endosomal‐lysosomal TLR4 pathway.[13](#hep41383-bib-0013){ref-type="ref"}, [16](#hep41383-bib-0016){ref-type="ref"} These results clarified that the nonenzymatic effect of LPL to increase TLR4 protein in HSCs was intracellular FC‐dependent. Lipopolysaccharide (LPS) administration reduced the mRNA expression of *Bambi*, a downstream molecule in TLR4 signaling, in primary cultured HSCs. Furthermore, the concurrent pre‐administration of chylomicrons or LDL significantly decreased the *Bambi* mRNA levels in *Lpl^fl/fl^* HSCs, whereas the decrease was not observed in *Lpl^HSC‐KO^* HSCs (Fig. [6](#hep41383-fig-0006){ref-type="fig"}C). Treatment with orlistat did not affect the expression of *Bambi* mRNA, and the simultaneous administration of cyclodextrin abolished the changes in Bambi expression induced by the administration of chylomicrons or LDL (Fig. [6](#hep41383-fig-0006){ref-type="fig"}C).

Finally, we examined the effect of LPL expression in HSCs on the TGF‐β‐induced HSC activation. The expression of *Col1a1*, *Col1a2*, and *Acta2* mRNA significantly increased following the administration of TGF‐β, but was not affected by the pre‐administration of chylomicrons or LDL (Fig. [6](#hep41383-fig-0006){ref-type="fig"}D). LPS pre‐administration enhanced the TGF‐β‐induced HSC activation, and significantly enhanced the increase in *Col1a1*, *Col1a2*, and *Acta2* mRNA expression caused by TGF‐β. In addition, in *Lpl^fl/fl^* HSCs, *Col1a1*, *Col1a2*, and *Acta2* expression was significantly increased by the pre‐administration of chylomicrons or LDL, but these changes were not observed in *Lpl^HSC‐KO^* HSCs (Fig. [6](#hep41383-fig-0006){ref-type="fig"}D). The increase in *Col1a1*, *Col1a2*, and *Acta2* mRNA expression induced by the pre‐administration of chylomicrons or LDL was abolished following cholesterol depletion by cyclodextrin. In addition, the simultaneous administration of orlistat did not affect the expression of *Col1a1*, *Col1a2*, and *Acta2* mRNA in HSCs (Fig. [6](#hep41383-fig-0006){ref-type="fig"}D).

LPL expression in HSCs did not significantly increase in the livers of patients with autoimmune hepatitis as another type of underlying human liver disease (Supporting Fig. [S6](#hep41383-sup-0006){ref-type="supplementary-material"}). Hepatic *LPL* mRNA expression was not significantly correlated with liver fibrosis stages in patients with NASH (Supporting Fig. [S7](#hep41383-sup-0007){ref-type="supplementary-material"}). LPL expression in HSCs also did not significantly increase in the mouse carbon tetrachloride (CCl~4~) model of liver fibrosis (Supporting Fig. [S8](#hep41383-sup-0008){ref-type="supplementary-material"}). Furthermore, there were no significant differences in liver fibrosis progression in the mouse CCl~4~ model of liver fibrosis between *Lpl^fl/fl^* and *Lpl^HSC‐KO^* mice (Supporting Fig. [S8](#hep41383-sup-0008){ref-type="supplementary-material"}).

Discussion {#hep41383-sec-0012}
==========

In the present study, we revealed a pathogenic mechanism underlying NASH development and a role for LPL in the pathology of this disease. In NASH, serum obesity‐related factors increased LPL expression, specifically in HSCs, through STAT3 signaling. The increase in LPL expression enhanced the accumulation of FC in HSCs by increasing cholesterol uptake, which promoted TLR4 signaling and the suppression of *Bambi* expression. As a result, HSCs became susceptible to TGF‐β‐induced HSC activation, and liver fibrosis was promoted in NASH.

LPL has been known to play a central role in the regulation of the lipid metabolism and control of the energy balance in the body by exerting its action primarily in the adipose tissue, skeletal muscle and heart,[7](#hep41383-bib-0007){ref-type="ref"} whereas LPL is barely expressed in the normal adult liver.[10](#hep41383-bib-0010){ref-type="ref"} Therefore, the roles of hepatic LPL in human pathology have remained unclear. Some studies[17](#hep41383-bib-0017){ref-type="ref"}, [18](#hep41383-bib-0018){ref-type="ref"} report that the expression of hepatic LPL mRNA is significantly elevated in human NAFL livers compared with that in normal livers; these reports did not address in which liver cells LPL expression was detected. Moreover, LPL overexpression in the mouse liver causes liver‐specific insulin resistance and exacerbates the accumulation of TG in the liver[19](#hep41383-bib-0019){ref-type="ref"}; this is presumed to be due to LPL overexpression in hepatocytes in an artificial state.

In the present study, we demonstrated that LPL expression is enhanced in HSCs, not in hepatocytes, in human and mouse NAFLD. In addition, the change in LPL expression in HSCs did not affect the hepatic TG accumulation, dyslipidemia, or insulin tolerance. Most previous reports on LPL expression in the liver have assumed that LPL is expressed only in hepatocytes; therefore, it is necessary to reexamine LPL expression in HSCs.

We have also shown that serum obesity‐related factors, such as leptin, IL‐6 and FFA, increase LPL expression in HSCs through STAT3 signaling in both humans and mice. NASH is often accompanied by obesity as a background factor, and it is assumed that obesity triggers NASH development. In obesity, the mobilization of FFA from the adipose tissue to the liver increases, which results in an exacerbation of fatty liver[20](#hep41383-bib-0020){ref-type="ref"} and the elevation of serum FFA.[21](#hep41383-bib-0021){ref-type="ref"} In addition, the serum concentrations of proinflammatory adipocytokines, such as leptin and IL‐6, significantly increase in obesity.[22](#hep41383-bib-0022){ref-type="ref"} In contrast, some reports, including ours,[12](#hep41383-bib-0012){ref-type="ref"}, [21](#hep41383-bib-0021){ref-type="ref"}, [22](#hep41383-bib-0022){ref-type="ref"}, [23](#hep41383-bib-0023){ref-type="ref"}, [24](#hep41383-bib-0024){ref-type="ref"}, [25](#hep41383-bib-0025){ref-type="ref"} have shown that the serum levels of obesity‐related factors significantly increase with the progression of NAFLD in humans and mice. Each obesity‐related factor is known to enhance STAT3 signaling.[26](#hep41383-bib-0026){ref-type="ref"}, [27](#hep41383-bib-0027){ref-type="ref"}, [28](#hep41383-bib-0028){ref-type="ref"} We have recently shown that these serum obesity‐related factors enhance STAT3 signaling in HSCs as NAFLD progresses.[12](#hep41383-bib-0012){ref-type="ref"} Furthermore, it has been reported that the putative STAT3‐binding site is present in the *LPL* promoter and that STAT3 signaling increases LPL expression.[29](#hep41383-bib-0029){ref-type="ref"} Our *in vivo* and *in vitro* studies have revealed that these elevated levels of serum obesity‐related factors increase LPL expression in HSCs in NAFLD through the activation of STAT3 signaling.

In the present *in vivo* and *in vitro* studies, the increased LPL expression in HSCs enhanced cholesterol uptake from serum lipoproteins into HSCs in an autocrine manner, independent of LPL activity. LPL is known to be a lipase with a key role in hydrolyzing TGs from TG‐rich lipoproteins, whereas many reports have shown that it has an additional bridging function, promoting the binding of different lipoproteins to their receptors, independent of its enzyme activity.[8](#hep41383-bib-0008){ref-type="ref"}, [9](#hep41383-bib-0009){ref-type="ref"}, [30](#hep41383-bib-0030){ref-type="ref"} LPL enhances lipoprotein uptake into various cells by pathways that are independent of LPL enzyme activity but require LPL as a molecular bridge between lipoproteins and heparan sulfate proteoglycans (HSPGs) or lipoprotein receptors.[31](#hep41383-bib-0031){ref-type="ref"}, [32](#hep41383-bib-0032){ref-type="ref"}, [33](#hep41383-bib-0033){ref-type="ref"}, [34](#hep41383-bib-0034){ref-type="ref"}, [35](#hep41383-bib-0035){ref-type="ref"} Thus, LPL can bridge lipoproteins and HSPGs, which could concentrate lipoproteins in the vicinity of receptors, resulting in a rapid receptor‐dependent uptake.[34](#hep41383-bib-0034){ref-type="ref"}, [36](#hep41383-bib-0036){ref-type="ref"} Alternatively, bound lipoproteins could be taken up by cells along with proteoglycans as the latter are recycled.[34](#hep41383-bib-0034){ref-type="ref"}, [36](#hep41383-bib-0036){ref-type="ref"} In our study, LPL in HSCs significantly increased cholesterol uptake into HSCs from each of the serum lipoproteins tested (chylomicrons, VLDL, and LDL), independent of its enzyme activity. We also revealed that LPL in HSCs plays a central role in the uptake of cholesterol into HSCs and the subsequent enhanced accumulation of FC in HSCs, as its deficiency significantly inhibits this uptake and decreases the accumulation of FC. LPL in HSCs had no effect on lipoprotein uptake or FC accumulation in the whole liver, which means that LPL in HSCs acts in an autocrine manner.

The increase in LPL expression led to the accumulation of FC in HSCs, which in turn increased the TLR4 protein levels. We showed that FC accumulation in HSCs increases TLR4 protein levels through the suppression of the endosomal‐lysosomal TLR4 pathway and, as a result, enhances TLR4 signaling.[13](#hep41383-bib-0013){ref-type="ref"}, [16](#hep41383-bib-0016){ref-type="ref"} In the present study, the administration of chylomicrons or LDL significantly increased the amount of FC in HSCs through nonenzymatic LPL function, and then the FC accumulation significantly increased TLR4 protein levels in HSCs. These results clarified that the LPL‐induced increase in TLR4 protein in HSCs was intracellular FC‐dependent, not transcriptionally mediated. Furthermore, we have shown that the exacerbation of the progression of liver fibrosis in NASH, due to the enhanced LPL expression in HSCs, is TLR4‐dependent. In HSCs with enhanced LPL expression, the expression of the TGF‐β‐pseudoreceptor Bambi, a downstream molecule involved in TLR4 signaling, decreased with TLR4 signal potentiation. This triggered the HSC susceptibility to TGF‐β‐mediated activation and resulted in the exacerbation of liver fibrosis in NASH. Conversely, LPL deficiency in HSCs had no effect on hepatocellular damage or macrophage activation in NASH, which suggests that HSC‐derived LPL could modulate the pathology of NASH, primarily by acting in an autocrine fashion.

Thus, in this study, we reveal pathological mechanisms underlying liver fibrosis in NASH and the role of LPL in the pathology of this disease. We showed that in NAFLD, serum obesity‐related factors increase LPL production, specifically in HSCs, but not in hepatocytes. The enhanced expression of LPL in HSCs increases cholesterol uptake from serum lipoproteins into HSCs, independently of LPL activity. Moreover, it makes HSCs susceptible to TGF‐β‐induced activation through FC accumulation, followed by an increase in TLR4 signaling; this further results in the exacerbation of liver fibrosis in NASH. Therefore, this LPL‐mediated HSC activation pathway may represent a promising therapeutic target for liver fibrosis in NASH, and large‐scale future clinical investigations should be considered.
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